key: cord-0874514-wq89wtwf
authors: Pirzada, Ashar; Mokhtar, Ahmed T.; Moeller, Andrew D.
title: COVID-19 and myocarditis: What do we know so far?
date: 2020-05-28
journal: CJC Open
DOI: 10.1016/j.cjco.2020.05.005
sha: 7aa65c8c30f7a2f84a3616795d8bb4742bdc0935
doc_id: 874514
cord_uid: wq89wtwf

COVID-19 has been declared a global pandemic by the World Health Organization and is responsible for hundreds of thousands of deaths worldwide. COVID-19 is caused by SARS-CoV-2, and common clinical symptoms include fever, cough, sore throat, headache, and fatigue. Myocardial injury is relatively common in COVID-19, accounting for 7-23% of cases, and is associated with a higher morbidity and mortality. There is a discrepancy in the literature about myocarditis as the etiology of myocardial injury in COVID-19; although many anecdotal reports of myocarditis have been noted, there are only a handful of case reports in the literature about myocarditis related to COVID-19. This review summarizes the most up-to-date literature around the association between COVID-19 and myocarditis and gives clinicians a practical framework about the clinical manifestations, diagnostic tools and treatment options currently available. Importantly, this review will heighten suspicion for myocarditis as an etiology of myocardial injury in COVID-19 patients, therefore improving clinical outcomes and encouraging shared clinical decision-making. This will also open the door for further research to build around this review. Emergent treatment options for COVID-19 are in clinical trials and may be of benefit to COVID-19 patients with myocarditis in addition to current guideline-based recommendations.

The Coronavirus disease has been declared as a global pandemic by the World Health Organization (WHO) (1,2). COVID-19 is a clinical syndrome caused by severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2). The hallmark of COVID-19 is respiratory involvement, ranging from mild upper respiratory symptoms to Acute Respiratory Distress Syndrome (ARDS) (2) . However, severe COVID-19 imparts multiorgan involvement, with several observational case series demonstrating a significant proportion of cardiac involvement among hospitalized patients (3, 4) . In addition, cardiac injury has shown disproportionate rates of mortality, with rates approaching 51% once cardiac involvement has been established (3) . COVID-19 has a wide spectrum of cardiovascular complications, including acute-onset heart failure, arrhythmias, acute coronary syndrome, myocarditis and cardiac arrest (3, 4) . Myocarditis is a potentially lethal complication, observed among cases of the current and previous outbreaks of other coronaviridae, such as Middle Eastern Respiratory Syndrome (MERS) (5) (6) (7) (8) . Given the relative novelty of COVID-19, the data surrounding the association between COVID-19 and myocarditis is still being published. The aim of this review is to examine the most updated literature surrounding COVID-19 and myocarditis.

The exact pathophysiology of severe COVID-19 disease is still elusive. However, a consistent observation is the presence of a pro-inflammatory surge, the so-called "cytokine storm". This is thought to be central to the pathogenesis of the acute lung injury-ARDS spectrum that amplifies the immune response of alveolar tissue (9) (10) (11) . This phenomenon is thought to be a contributory factor to myocardial injury, observed in other forms of viral infections, such as H1N1 (12) . Huang et al (9) demonstrated this among a cluster of 41 patients with COVID-19. Patients who required intensive care (n=13) showed higher plasma concentrations of cytokines and chemokines, including GCSF, IP10, MCP1, MIP1A, and TNFα. However, it is unknown if myocarditis is the actual cause of the troponin rise in this case series, as the authors did not report data showing correlative cardiac outcomes or demonstration of LV dysfunction.

Chen and colleagues also had a similar observation, with elevation of IL-2R, IL-6, IL-10, and TNFα among the cohort of severe COVID-19 patients in a single-centre retrospective study (11) . Cytokine storm is not unique to severe COVID-19, as both MERS-CoV and SARS-CoV have shown cytokine surge syndrome among the spectrum of coronavirus disease (13, 14) . Whether this phenomenon is the main cause of fulminant myocarditis still uncertain (Figure 1 ). It is currently unknown whether the response is purely related to inflammation, autoimmunity, or a combination of both as seen in other types of viral myocarditis (15) .

Another potential cause of myocarditis is direct viral involvement. SARS-CoV-2 utilizes the angiotensin-converting enzyme 2 (ACE2) via its S-spike to bind and anchor to the receptors, hence an entry point to the cell (16, 17) . Hence, it is reasonable to consider viral inclusion or associated myocardial inflammation as the pathogenesis of myocarditis. This direct myocardial involvement was seen in MERS, with one report showing evidence of subepicardial late gadolinium enhancement (LGE), consistent with myocarditis (6) . In this case, the distribution of LGE in the sub-epicardial region is consistent with myocarditis.

So far, there are limited reports demonstrating pathological evidence that COVID-19 directly invades the heart (18). Sala et al showed viral particles with the morphology and size of coronaviruses in interstitial macrophages, however there was no SARS-CoV-2 genomic material in the myocardium. In another study, Xu et al reported pathological post-mortem biopsies from a patient who succumbed to COVID-19. There were only a few interstitial mononuclear inflammatory infiltrates, but no other substantial damage in the heart tissue (4). 

Outside of published case reports, the exact incidence of myocardial involvement or myocarditis among hospitalized COVID-19 patients is unknown. However, several observational studies have reported cardiac injury among hospitalized COVID-19 patients (3, 19, 20) . Most cohorts defined myocardial injury as detectable serum troponin above the 99 th percentile of the upper reference limit. So far, the largest cohort examining the association between cardiac involvement and COVID-19 was performed at the index epicenter in China (3) . From a cohort of 416 patients at the Renmin Hospital of Wuhan University, 82 patients (19.7%) had cardiac injury. Mortality among the myocardial injury group was significantly higher (51.2% vs 4.5%, p < .001). Cardiac involvement among this cohort of patients showed a hazard ratio of 4.26. Ruan et al reported a multicenter, retrospective review of 150 patients with confirmed COVID-19 (20) . 68 patients died, with five patients (7%) dying of heart failure and 22 patients (33%) dying of both respiratory and heart failure. The cohort with higher deaths consistently had higher levels of troponin and myoglobin. The authors speculate that some of these patients have died of COVID-19 induced fulminant myocarditis, but no reports on autopsies or biopsies were provided.

Myocarditis can have a variety of clinical presentations, ranging from mild symptoms such as fatigue, chest pain and palpitations to life-threatening presentations such as cardiogenic shock or sudden cardiac death associated with ventricular arrhythmias (Table 1) (21) . Classically, myocarditis has a viral prodrome including fevers, myalgias, and respiratory/gastrointestinal symptoms but this can be exceedingly variable, with ranges of 10 to 80% (22, 23) . Myocarditis is more common in males, with a male/female ratio between 1.5:1 and 1.7:1 (24).

COVID-19 patients predominantly present with fever, cough and dyspnea (23) . A meta-analysis of 10 studies including 1995 COVID-19 patients demonstrated that common symptoms were fever (88.5%), cough (68.6%), myalgia or fatigue (35.8%), expectoration (28.2%), and dyspnea (21.9%); minor symptoms included headache or dizziness (12.1%), diarrhea (4.8%), nausea and vomiting (3.9%) (23) . Other infrequent symptoms such as abdominal pain, constipation, chest pain, palpitations, chills, and anorexia accounted for 7-42% of presentations altogether (21) .

A cohort study from Wuhan, China involving 416 hospitalized patients with confirmed COVID-19 infection showed that chest pain accounted for 3.4% of presentations (3) . Hospitalized patients with a rise in troponin level were more likely to present with chest pain than those without a rise a troponin (11 of 82 patients [13.4%] vs 3 of 334 patients [0.9%]; P < .001). Established myocarditis is a relatively rare sequelae of COVID-19 infection. In the reported COVID-19 cases with myocarditis in the literature, clinical presentations have varied ( Table 2) . There is potential overlap in symptomatology in patients with primary COVID-19 infection and COVID-19 patients with clinically suspected myocarditis. 

Significant serum troponin elevation has been observed among several cases of severe COVID-19, which may indicate cardiac involvement (25) . A study by Zhou et al demonstrated that highsensitivity troponin I levels (hs-cTnI) was significantly greater by day 4 in COVID-19 nonsurvivors vs survivors (8.8pg/mL vs 2.5 pg/mL). Myocardial injury is a predictor of mortality and more severe illness in COVID-19 confirmed patients (26) . However, troponitis in isolation is not diagnostic of myocarditis and requires other supplementary findings and investigations. Furthermore, troponin elevation in the setting of severe COVID-19 could be a reflection of supply demand mismatch, rather than overt myocardial injury (27) . Other biomarkers, such as natriuretic peptides (NT-proBNP) are not sensitive or specific in diagnosing myocarditis (21) .

ECGs are usually abnormal in myocarditis, however specific abnormalities on ECG lack sensitivity and specificity (28) . Dynamic ECG changes have been documented in critically ill COVID-19 patients (29) . In two cases reported by He et al, dynamic ECG changes were noted when hospitalized COVID-19 patients deteriorated clinically. In one case, a patient's baseline ECG was sinus rhythm with first-degree AV block, which progressed to high-grade AV block before returning to baseline within 2 days. It was undetermined if these cases had myocarditis. Nevertheless, dynamic ECG changes in COVID-19 patients may be a harbinger of clinical deterioration and should be recorded in all hospitalized COVID-19 patients.

•Acute chest pain •ST/T wave changes •With or without normal global or regional LV and/or RV dysfunction on echocardiography or CMR •With or without increased TnT/TnI that may have a time course similar to acute myocardial infarction or a prolonged and sustained release over several weeks or months

(1) Acute coronary syndrome-like •New onset or progressive heart failure over 2 weeks to 3 months •Impaired systolic LV and/or RV function, with or without an increase in wall thickness, with or without dilated LV and/or RV on echocardiography or CMR •Symptoms possibly started after a respiratory or gastrointestinal infection, or in the peri-partum period •Non-specific ECG signs, bundle branch block, AV-block, and/or ventricular arrhythmias

(2) New onset or worsening heart failure in the absence of CAD and known causes of heart failure •Heart failure symptoms (with recurrent exacerbations) of >3 months duration •Fatigue, palpitation, dyspnea, atypical chest pain, arrhythmia in an ambulant patient •Impaired systolic LV and/or RV function on echocardiography or CMR suggestive of DCM or non-ischemic cardiomyopathy •Non-specific ECG signs, sometimes bundle branch block and/or ventricular arrhythmias and/or AV-block (3) Chronic heart failure in the absence of CAD and known causes of heart failure (see point 2 above)

•Life-threatening arrhythmias and aborted sudden death •Cardiogenic shock •Severely impaired LV function (4) 'life-threatening condition', in the absence of CAD and known causes of heart failure comprising Echocardiography is an important first-line non-invasive test in the workup for myocarditis. TTE can help rule out other causes of heart failure such as myocardial infarction and valvular heart disease (30) . TTE findings can include global LV hypokinesis, regional wall motion abnormalities, dilated and/or hypertrophic ventricles (31) . In the case reports of suspected myocarditis in COVID-19 patients (Table 2) , all TTEs revealed reduced LVEF. Given the need for close contact to obtain images, The Canadian Society of Echocardiography (CSE) recommends that among COVID-19 positive or suspected patients, point-of-care ultrasound (POCUS) should be highly considered as an initial screening test (32) . Subsequently the initial findings would determine whether a definitive TTE is required.

In typical circumstances, prior to the COVID-19 pandemic, cardiac magnetic resonance imaging (CMR) is an integral test in the diagnosis of myocarditis, especially if endomyocardial biopsy (EMB) is not pursued or cannot be obtained, (33) . CMR using the Lake Louise criteria has a specificity of up to 91% and a sensitivity of 67% for diagnosing myocarditis (34) . CMR is not indicated in unstable patients presenting with severe heart failure, circulatory shock, ventricular arrhythmia or high-grade AV block and EMB should be obtained (34) . If CMR is available and there are no contraindications to testing, CMR can safely be used as a first-line diagnostic tool in the workup of myocarditis associated with COVID-19 (35) . This is demonstrated in the current literature, as several authors have used CMR fulfilling the Lake Louise criteria for diagnosing patients with myocarditis associated with COVID-19 (7, 18, (36) (37) (38) (39) (40) . Clinical reasoning should drive the pursuit of definitive investigations when COVID19 myocarditis is suspected.

EMB is recommended, but is not required, in certain clinical situations to aid in the diagnosis of myocarditis. (24) . Histologic analysis typically reveals inflammatory infiltrates with myocyte degeneration and non-ischemic necrosis (21). Xu et al was the first to report interstitial mononuclear inflammatory infiltrates in a post-mortem biopsy of a COVID-19 patient (4). In another histopathologic study involving three patients, all patients had small amounts of lymphocyte, monocyte and neutrophil infiltration in heart tissue but PCR did not detect COVID-19 in myocardial tissue (41) . A case reported by Sala et al showed diffuse T-lymphocytic inflammatory infiltrates (CD3+ >7/mm²) with interstitial edema, but no COVID-19 genome in the myocardium (36) . Furthermore, Tavazzi et al showed viral particles typical of coronavirus involving interstitial macrophages and their surroundings, but not within the cardiac myocytes (18) . Myocarditis can be an incidental finding in autopsy studies of patients who died from a non-cardiac cause. Therefore, the implication of finding myocardial inflammation should always be interpreted in context of specific clinical scenarios (19) . To date, EMB evidence of direct viral invasion into myocardium has not been demonstrated in cases of suspected COVID-19 myocarditis, which is limited by paucity of published pathologic data.

To summarize, there is no single test or exam that allows for diagnosis of myocarditis, as the diagnosis requires a combination of clinical findings, biomarkers, imaging and pathology when indicated.

There is some randomized controlled trial (RCT) data regarding management of myocarditis patients, and guideline recommendations are based on expert consensus (42) . Patients with suspected myocarditis due to COVID-19 should be treated according to current guideline recommendations for heart failure and arrhythmia (21, 33, 42) . Heart failure is common (>20%) in hospitalized COVID-19 patients and it is unclear whether this is primarily due to deterioration of pre-existing left ventricular function, new-onset myocarditis or a combination of factors (26) .

The routine use of steroids and other immunosuppressive strategies in all patients with myocarditis is not recommended (33) . The Myocarditis Treatment Trial is the largest RCT to study immunosuppression in myocarditis, randomizing 111 patients with EMB-proven myocarditis to prednisone + azathioprine, prednisone + cyclosporine and placebo (43) . There was no statistical difference in the primary endpoint of LVEF at 28 weeks. Systemic steroids and immunosuppression are not currently recommended for COVID-19 patients as it may exacerbate COVID-19-associated lung injury (44) . Given that a subset of these patients present with cytokine storm, and emerging data shows immunosuppression may be beneficial in these patients (10) . There are ongoing clinical trials with options including steroids, intravenous immunoglobulin, selective cytokine blockade (eg, anakinra or tocilizumab) and JAK inhibition (ChiCTR2000029765) (45) . Although the cases of COVID-19 patients with myocarditis were treated with steroids, it is unclear the incremental benefit these therapies may have provided over supportive care. There is insufficient evidence to recommend systemic immunosuppression for suspected COVID-19 myocarditis at this time. Antiviral therapy has been used previously in viral myocarditis. However, RCTs of these therapies have not established myocarditis-causing viruses, such as enterovirus or adenovirus, as therapeutic targets (46) . For example, the BICC trial randomized patients with EMBconfirmed viral cardiomyopathy to receive placebo or interferon-B. Viral clearance was not enhanced in all virus subtypes. Antiviral therapy is under investigation for the treatment of COVID-19. Lopinavir/Ritonavir is a combination antiviral agent primarily used for treatment of HIV which is undergoing clinical trials for COVID-19. One RCT did not show any benefit in mortality compared to placebo, and lopinavir/ritonavir can be associated with long QT interval (47) . To date, there is no antiviral therapy that is known to be of benefit to COVID-19 patients.

As seen in Table 2 , published case reports highlight the variability in presentation of COVID-19 associated myocarditis. However, supportive therapy is still the current mainstay of management, as there is still no clear signal that any combination of immunosuppression improves outcomes among patients with myocarditis. This variability in practice is highlighted in the published case series. Steroid monotherapy (7, 37) , steroid and IL-6 inhibitor combination therapy (38) and antiviral monotherapy with no immunomodulation (5) have all been used to date in cases of COVID-19 associated myocarditis. The benefits of immunosuppression in treating contemporary fulminant myocarditis are yet to be determined. Figure 2 summarizes the general clinical approach among published case reports of COVID-19 associated myocarditis.

Patients with myocarditis can clinically deteriorate or develop end-organ dysfunction despite standard heart failure therapy and supportive care. Prior to the COVID-19 pandemic, cases of end-stage, non-COVID-19 associated myocarditis could be referred for mechanical circulatory support (MCS) and/or consideration of heart transplantation (33) . MCS as a bridge to recovery has been successful in fulminant myocarditis (48) . Zeng et al reports the first case of fulminant myocarditis requiring MCS with ECMO as a successful bridge to recovery in a COVID-19 patient (45) . Heart transplantation would not be an option for patients with COVID-19 associated myocarditis due to their active and ongoing infection (33) .

Myocardial injury is common in patients with COVID-19, accounting for 7-23% of reported cases in Wuhan, China (9, 49, 50) . Among COVID-related myocardial injury, etiologies vary and are can include myocarditis, myocardial infarction, sepsis-related myocardial injury and/or stressinduced cardiomyopathy (51) . Further prospective cohort and case series data is needed to better characterize the exact mechanism of injury in myocarditis related to COVID-19. Due to the low prevalence of disease, this will most likely require multi-site collaboration and endeavours. Clinically suspected myocarditis is a rare cause of myocardial injury, has heterogeneous clinical presentations and is likely underdiagnosed in critically ill patients with COVID-19. Due to potential for rapid deterioration in COVID-19 patients with myocarditis, it is imperative to be aware of myocarditis as a sequela of COVID-19 and a multi-disciplinary team should be formed for all COVID-19 patients with clinically suspected myocarditis. Further studies are needed to better recognize and understand the association of myocarditis and COVID-19. 

WHO Director-General's remarks at the media briefing on 2019-nCoV on 11

Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

First case of COVID-19 infection with fulminant myocarditis complication: case report and insights

Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

Coronavirus fulminantmyocarditis treated with glucocorticoid and human immunoglobulin

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Correspondence COVID-19 : consider cytokine storm syndromes and

Clinical and immunologic features in severe and moderate forms of Coronavirus Disease

A national survey on myocarditis associated with the 2009 influenza A (H1N1) pandemic in Japan

Into the eye of the cytokine storm

MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile

Autoimmunity in viral myocarditis

ACE2: from vasopeptidase to SARS virus receptor

ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Meta-analysis of the association of enteroviruses with human heart disease

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

Sex and gender differences in myocarditis and dilated cardiomyopathy

COVID-19 and the Heart

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prognostic significance of elevated cardiac troponin-T levels in acute respiratory distress syndrome patients

Prognostic electrocardiographic parameters in patients with suspected myocarditis

Characteristic ECG Manifestations in Patients with COVID-19

Imaging of myocarditis and inflammatory cardiomyopathies

Diuretic strategies in patients with acute decompensated heart failure

Practice of Echocardiography During the COVID-19 Pandemic : Guidance from the Canadian Society of

Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure

Cardiovascular magnetic resonance in myocarditis: A JACC White Paper

Society for Cardiovascular Magnetic Resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes

A Recovered Case of COVID-19 Myocarditis and ARDS Treated with Corticosteroids, Tocilizumab, and Experimental AT-001

Diffuse Myocardial Inflammation in COVID-19 Associated Myocarditis Detected by Multiparametric Cardiac Magnetic Resonance Imaging

COVID-19-related myocarditis in a 21-year-old female patient

Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study

A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Clinical trial analysis of 2019-nCoV therapy registered in China

Management of Myocarditis-Related Cardiomyopathy in Adults

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Mechanical circulatory support for patients with acute-fulminant myocarditis

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Hear Rhythm